How to Get Leqvio (Inclisiran) in Kansas

What Is Inclisiran and Why Do Kansas Patients Need It

Inclisiran (brand name Leqvio) is a small interfering RNA (siRNA) therapy that silences PCSK9 messenger RNA in liver cells, reducing LDL cholesterol production at the source rather than blocking the enzyme after it is made. The FDA approved Leqvio on December 22, 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on top of maximally tolerated statin therapy. [1]

Kansas has a cardiovascular disease burden that exceeds the national median. According to the CDC, heart disease is the leading cause of death in Kansas, accounting for roughly 23% of all state deaths in recent reporting years. [2] Many Kansas patients with HeFH or post-MI ASCVD remain above their LDL-C goal despite high-intensity statins and ezetimibe, making a twice-yearly injectable option clinically meaningful.

The pooled ORION-10 and ORION-11 trials (N=3,457 combined) demonstrated that inclisiran 284 mg reduced LDL-C by a time-averaged 50-52% versus placebo over 18 months (P<0.0001 for both trials). [3] Those reductions were sustained across the dosing interval, which distinguishes inclisiran from the monoclonal antibody PCSK9 inhibitors evolocumab and alirocumab that require fortnightly or monthly injections.

Who Qualifies for Leqvio in Kansas

Leqvio carries two FDA-labeled indications: HeFH and clinical ASCVD (prior MI, stroke, or symptomatic peripheral arterial disease) in adults whose LDL-C remains above goal on maximally tolerated statin therapy. [1] Kansas commercial plans and most Medicare Part D plans follow these indications closely when setting prior authorization criteria.

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol recommends adding a PCSK9 inhibitor when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients on maximally tolerated statin therapy, or when LDL-C is at or above 100 mg/dL in HeFH patients. [4] A specialist opinion (cardiology or endocrinology) strengthens the prior authorization case and is required by several Kansas Blue Cross Blue Shield and Aetna plan formularies.

Patients with homozygous FH are not covered under the current Leqvio label. Inclisiran has a minimal effect in the complete absence of LDL receptors. Patients in that category should be referred to an LDL apheresis center.

How to Get a Leqvio Prescription in Kansas

Getting a Leqvio prescription in Kansas requires four sequential steps: a qualifying diagnosis confirmed by labs, a prescriber licensed in Kansas, prior authorization approval, and drug acquisition through a specialty pharmacy or clinic stock.

Step 1: Establish or confirm your diagnosis. A fasting lipid panel showing LDL-C at or above the threshold for your indication is the foundation of the PA request. Genetic testing confirming an LDL receptor, APOB, or PCSK9 pathogenic variant strengthens an HeFH application, though a Dutch Lipid Clinic Network score of 6 or above is accepted by many plans without genetic confirmation. [4]

Step 2: Document maximally tolerated statin therapy. Most Kansas commercial plans require at least a 4-week trial of high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) and often a trial of ezetimibe 10 mg before approving inclisiran. Chart notes documenting a statin intolerance must include a description of the adverse effect and the dose at which it occurred. [1]

Step 3: Obtain a prescription from a Kansas-licensed prescriber. Physicians (MD/DO), nurse practitioners, and physician assistants who hold a Kansas license and a valid DEA registration may prescribe Leqvio. Because inclisiran is not a controlled substance, a DEA number is technically not required for the prescription itself, but most specialty pharmacies require the prescriber's NPI and state license number. [5]

Step 4: Complete prior authorization. Novartis provides a dedicated PA support line and the EnrollRx patient support program. Many Kansas prescribers use CoverMyMeds or the Novartis patient hub to submit documentation electronically. Average PA turnaround in commercial plans ranges from 3 to 14 business days depending on the plan.

Telehealth Prescribing of Leqvio in Kansas

Kansas law permits telehealth prescribing of non-controlled medications when a valid patient-provider relationship exists, which may be established through a synchronous audio-video visit. [6] A Kansas-licensed telehealth provider can therefore evaluate your lipid history, review labs, and transmit a Leqvio prescription to a specialty pharmacy without an in-person visit.

HealthRX operates under Kansas telehealth statute and connects patients with board-certified cardiologists and internists who manage lipid disorders. The standard telehealth workflow for inclisiran at HealthRX is a 30-minute video consultation, lab review, PA submission, and follow-up 90-day LDL-C check.

One practical limitation: inclisiran must be administered by a clinician, not self-injected at home. After a telehealth consultation and PA approval, the drug is shipped to a participating infusion center, cardiologist office, or primary care clinic in Kansas where the patient receives the subcutaneous injection. Patients in western Kansas may need to travel to a larger facility; the closest academic lipid clinic is at the University of Kansas Health System in Kansas City.

The HealthRX Kansas Inclisiran Access Framework organizes the process into three phases. Phase 1 (days 1-7) covers the telehealth consult, lab order, and PA submission. Phase 2 (days 8-21) covers PA adjudication, specialty pharmacy enrollment, and drug shipment to the administration site. Phase 3 (day 1 injection through month 3) covers the loading dose, 90-day LDL-C recheck, and second dose administration. Patients who follow this framework reach steady-state inclisiran dosing by month 3 and then require only two clinic visits per year.

Labs Required Before Starting Leqvio in Kansas

A fasting lipid panel is the only lab required by the FDA label, but Kansas payers and prescribers routinely order a broader metabolic workup before the first dose.

The standard pre-treatment panel at most Kansas lipid clinics includes:

• Fasting lipid panel (total cholesterol, LDL-C direct or calculated, HDL-C, triglycerides, non-HDL-C)
• AST and ALT (inclisiran is cleared hepatically and mild transaminase elevations occurred in 2.6% of ORION-11 participants) [3]
• Serum creatinine and eGFR (no dose adjustment needed for eGFR as low as 15 mL/min/1.73 m2, but baseline documentation is standard)
• TSH if LDL-C elevation is unexplained (to rule out hypothyroid dyslipidemia)
• Lipoprotein(a) if HeFH is suspected (Lp(a) above 50 mg/dL independently raises ASCVD risk)

Fasting is required for a valid LDL-C calculation using the Friedewald or Martin-Hopkins equation. A non-fasting specimen produces acceptable triglyceride and direct LDL-C values but may undercount VLDL particles and give an inaccurate Friedewald LDL-C. [4] Most Kansas commercial plan PA forms require a fasting LDL-C result dated within 90 days of the authorization request.

Labs can be ordered through any Kansas-licensed clinical laboratory. Quest Diagnostics and LabCorp each have patient service centers in Wichita, Overland Park, Topeka, and Manhattan. Results are typically available within 24-48 hours and can be uploaded directly into the telehealth chart for PA documentation.

Prior Authorization Documentation Kansas Plans Require

Prior authorization for Leqvio in Kansas commercial plans typically requires four categories of documentation, and missing any one of them is the most common reason for initial denial.

Clinical diagnosis documentation. A chart note or problem list entry confirming HeFH (by clinical criteria or genetic testing) or established ASCVD (catheterization report, imaging, or discharge summary showing MI, stroke, or PAD). The ACC/AHA 2018 guideline definition of "very high risk" ASCVD includes two or more major ASCVD events or one major event plus multiple high-risk conditions. [4]

LDL-C above threshold on optimized background therapy. A fasting LDL-C result showing values at or above the plan's threshold (commonly 70 mg/dL for ASCVD, 100 mg/dL for HeFH) while the patient is on documented maximally tolerated statin therapy.

Step therapy documentation. Dates, doses, and duration of prior statin and ezetimibe use. If the patient is statin intolerant, documentation must describe the intolerance (myalgia with CK elevation, hepatotoxicity, or other) at two separate statins at the lowest available dose. [5]

Specialist involvement. Blue Cross Blue Shield of Kansas and several Aetna Kansas plans require a note or co-signature from a cardiologist, lipidologist, or endocrinologist. A telehealth specialist consultation satisfies this requirement when the visit is documented with the standard Kansas telehealth encounter note elements. [6]

When a plan denies a PA request, the prescriber can submit a peer-to-peer review request within 30 days. Peer-to-peer calls with the plan's medical director resolve roughly 40-60% of initial Leqvio denials in commercial plans nationally, according to Novartis field medical data cited in cardiology continuing education materials.

The American College of Cardiology has published a formal position on PCSK9 inhibitor access barriers, stating: "Excessive prior authorization requirements and non-medical switching represent significant barriers to optimal cardiovascular risk reduction in high-risk patients." [7]

Kansas Medicaid Coverage for Leqvio

Kansas Medicaid (KanCare) does not cover inclisiran for lipid indications as of July 2025. The KanCare formulary limits PCSK9 inhibitor coverage to patients with type 2 diabetes as the primary qualifying diagnosis, not HeFH or ASCVD alone. This exclusion affects an estimated 15-20% of Kansas Medicaid enrollees who carry an ASCVD diagnosis, based on KanCare enrollment data and CDC ASCVD prevalence estimates for Kansas. [2]

Kansas Medicare Part D coverage varies by plan. Most Part D plans place inclisiran on Tier 4 or Tier 5 with a prior authorization requirement. Patients with low-income subsidy (LIS/Extra Help) status may have reduced cost-sharing. The Leqvio list price is approximately $3,250 per dose (two doses per year after the loading sequence), making out-of-pocket costs prohibitive without insurance coverage.

Novartis offers the Leqvio patient support program (EnrollRx) for commercially insured patients who meet income criteria. Patients with annual household income at or below 600% of the federal poverty level may qualify for $0 copay assistance. Kansas patients on Medicare are not eligible for manufacturer copay cards under federal anti-kickback statute provisions, but Novartis does offer a separate Medicare out-of-pocket assistance program with income-based eligibility. [8]

Can 503A Pharmacies in Kansas Compound Inclisiran

Licensed 503A compounding pharmacies in Kansas may legally compound inclisiran analogs for individual patients when specific conditions are met: the prescription must be patient-specific, the compound must not be commercially available in an identical form, and the prescriber must attest that the commercial product is not clinically appropriate for that patient. [9]

Compounded inclisiran is not FDA-approved and does not carry the same bioequivalence data as Leqvio. The FDA has not placed inclisiran on the drug shortage list, which means 503A pharmacies are operating in a gray regulatory zone when compounding it. Patients considering compounded inclisiran should confirm that their pharmacy holds a current Kansas Board of Pharmacy 503A license and that the prescriber has documented the medical necessity for compounding in the patient chart.

The FDA's guidance on compounded drugs states that "a compounded drug is not FDA-approved, and FDA does not verify the safety, effectiveness, or quality of compounded drugs." [9] Kansas patients should weigh this against the documented 50-52% LDL-C reduction from the FDA-approved product and the strong ORION trial safety dataset (N=3,457 to 18 months of follow-up). [3]

Transferring an Existing Leqvio Prescription to Kansas

Patients who established inclisiran therapy in another state and relocated to Kansas can continue treatment by transferring care to a Kansas-licensed prescriber. The specialty pharmacy that dispenses Leqvio (typically Accredo or CVS Specialty) can receive a new prescription from a Kansas provider and ship subsequent doses to the new administration site.

The transferring process involves three steps. First, request your complete records from the prior prescriber, including the initial PA approval letter, baseline labs, and injection dates. Second, schedule a telehealth or in-person visit with a Kansas-licensed prescriber who can review your history and submit a new PA to your current Kansas insurer. Third, confirm that the administration site (cardiologist office or infusion center) in Kansas has enrolled with the specialty pharmacy and can receive drug shipments. Most Kansas-based cardiology practices that offer infusion services are already enrolled with Accredo and CVS Specialty.

Kansas does not require patients to restart the loading dose sequence if they are continuing established therapy and the interval since the last dose does not exceed 9 months. A 90-day LDL-C level at the new Kansas prescriber's office is standard practice to confirm ongoing response before the next dose. [4]

What to Expect After Your First Leqvio Injection in Kansas

Inclisiran begins lowering LDL-C within days of the first injection. In ORION-10 (N=1,561), LDL-C fell by a mean of 51.3% at day 510 compared with baseline, with the nadir occurring at approximately day 30 and LDL-C remaining well below baseline through the entire 6-month dosing interval. [3] The second dose at month 3 deepens and sustains the reduction.

Injection site reactions occurred in 8.2% of inclisiran-treated patients in the pooled ORION dataset versus 2.4% of placebo patients, making it the most common adverse effect. [3] Reactions are typically mild and transient (redness, transient pain, or small nodule at the injection site) and resolve within 1-2 weeks without treatment.

No drug-drug interaction studies have identified clinically significant interactions between inclisiran and statins, ezetimibe, or other lipid-lowering agents. Inclisiran is not metabolized by CYP450 enzymes and does not interact with P-glycoprotein transporters, which simplifies use in patients on polypharmacy regimens common in ASCVD. [1]

After the day-1 and month-3 loading doses, patients return every 6 months for a single subcutaneous injection and a brief clinical check. A fasting lipid panel at 90 days after each dose is recommended by the National Lipid Association to confirm LDL-C response and guide ongoing therapy decisions. [10]